The Weekly Recap 10/3/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, achieve clinical and regulatory milestones, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).

Adagio Medical

Completed enrollment of the FULCRUM-VT pivotal FDA IDE study evaluating its ventricular tachycardia-specific ablation technology, with 208 patients across 20 centers. Adagio’s vCLAS™ Cryoablation System, which uses proprietary ultra-low temperature cryoablation (ULTC) technology, is being evaluated to support FDA pre-market approval for the treatment of monomorphic ventricular tachycardia.

AiM Medical Robotics

Raised $8.1M in Series A funding to advance its MRI-compatible surgical robotics platform for neurosurgery applications. The company will use the proceeds to fund its first-in-human clinical study, expand strategic partnerships, and accelerate product development and regulatory progress.

CorWave

Reported encouraging first patient results from its first-in-human study evaluating the CorWave LVAS for advanced heart failure. The membrane-based device demonstrated full circulatory support with preserved physiologic pulsatility and no device-related adverse events at 30 days, supporting its potential to reduce complications and improve patient outcomes.

Cyber Surgery

Launched ALAYA, the first CE-certified surgical robotic assistant for spine procedures with patented Kinematic Navigation Technology. Cyber Surgery’s debut product delivers continuous tracking, faster setup, and reduced radiation exposure, marking a significant milestone for European surgical robotics and advancing the company’s commercialization and international growth.

DeepSight Technology

Appointed Dr. Bradford Wood as Vice President of Strategic Partnerships, bringing decades of leadership in interventional radiology, interventional oncology, and image-guided minimally invasive therapies to DeepSight. The interventional imaging pioneer joins DeepSight to accelerate the adoption of its NeedleVue™ systems and expand strategic collaborations across hospitals, research institutions, and industry partners.

DermaSensor

Raised $16M in Series B funding to accelerate the commercial expansion of its FDA-cleared, AI-powered skin cancer detection technology. The handheld spectroscopy platform has scanned over 20,000 lesions since mid-2024 and will support pipeline programs and clinical validation efforts following pivotal data showing it halves missed skin cancer rates.

Distalmotion

Received a third FDA clearance for the DEXTER^Ⓡ Robotic Surgery System, expanding its U.S. indications to include total benign hysterectomy and other gynecologic procedures. The clearance reflects growing demand for outpatient robotic solutions and builds upon prior FDA clearances for inguinal hernia repair and cholecystectomy.

EndoQuest Robotics

Announced the completion of the first procedure performed by a gastroenterologist in the PARADIGM Trial, a pivotal multicenter study evaluating EndoQuest’s Endoluminal Surgical (ELS) System for use in lower GI tract procedures. Dr. Norio Fukami successfully performed a robotic endoscopic submucosal dissection (ESD) using EndoQuest’s ELS System, removing a complex colorectal lesion measuring 4 cm.

IBEX Medical Analytics

Appointed Dan McSweeney as Chief Revenue Officer to lead commercial strategy and growth. McSweeney brings more than 25 years of experience as a healthcare technology executive, with a strong track record of integrating imaging, advanced visualization, decision support, and AI into clinical workflows.

Navigation Sciences

Was awarded a $400K STTR Phase 1 grant from the National Cancer Institute to advance the NaviSci™ System for precision lung cancer surgery. The funding will support the development of the EndoNaviSci™ software to guide accurate J-Bar deployment close to nodules using diagnostic CT images from an inflated lung and determine the cutline distance in the deflated lung during surgery.

Panda Surgical

Raised £1M in strategic funding to advance its handheld neurosurgical robotics platform. The investment, led by Oxford Investment Consultants and supported by UCLB and New Wave Ventures, will accelerate the company’s upcoming first-in-human clinical investigation for its dexterous robot for minimally invasive neurosurgery.

Pylon Medical

Successfully completed an animal trial at Lahav CRO, achieving a 100% success rate in artery closure with its innovative vascular closure technology. The study represents a key step forward for Pylon Medical’s mission to bring safer and more effective solutions to patients undergoing vascular procedures.

SpectraWAVE

Appointed Dr. Jonathan Hill as Chief Medical Officer to lead global clinical strategy. A renowned interventional cardiologist with deep expertise in intravascular imaging, physiology, and complex PCI, Dr. Hill’s appointment strengthens SpectraWAVE’s clinical leadership as it expands commercial adoption of HyperVue™ and advances new technologies.

Vicarious Surgical

Appointed Joseph Doherty as Chairman of the Board of Directors to guide the company’s next phase of growth. A seasoned executive with leadership roles at Olympus, Johnson & Johnson, and Scapa Group, Doherty brings deep industry expertise and strategic insight as Vicarious Surgical advances development of its surgical robotics platform.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.